Navigation Links
Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
Date:8/6/2008

SAN CARLOS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Randall Moreadith, M.D., Ph.D., to the position of Senior Vice President of Drug Development and Chief Development Officer effective August 11, 2008. Dr. Moreadith will report to Nektar's President and Chief Executive Officer, Howard W. Robin.

Dr. Moreadith will lead Clinical Drug Development, Clinical Pharmacology and Toxicology, and Regulatory Affairs at Nektar. He is responsible for overseeing all aspects of drug development at the company and will drive clinical and regulatory strategy.

"We are delighted to have someone of Randall's caliber join the Nektar executive team as we execute on our proprietary drug development strategy," said Howard W. Robin, President and Chief Executive Officer of Nektar Therapeutics, "Randall is a highly experienced clinical research and product development executive with an impressive track record of accomplishments. His experience and leadership will allow us to rapidly build and strengthen our drug development organization."

Prior to joining Nektar, Dr. Moreadith, 54, was Executive Vice President and Chief Medical Officer of Cardium Therapeutics. While at Cardium, Dr. Moreadith led the advancement of novel DNA-based therapeutics into Phase 2b and Phase 3 late-stage development. Prior to Cardium, Dr. Moreadith served as Chief Medical Officer of Renovis, Inc. where he led the Clinical, Regulatory and Quality Assurance Group. Prior to that, Dr. Moreadith was co-founder, President and Chief Operating Officer of ThromboGenics Ltd., a leader in the field of thrombosis. During his tenure at ThromboGenics, the company advanced four biologics into mid-stage development.
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
2. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
3. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
4. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
6. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
8. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
9. Nektar Therapeutics Announces First Quarter 2008 Results
10. Prime Therapeutics Receives TIPPS Certification
11. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... CT (PRWEB) July 22, 2014 ... to meet new Department of Transportation regulations: all ... examiners for the US Department of Transportation (DOT). ... the road, the DOT enforces strict standards to ... to operate limousines, taxis, trucks, and other commercial ...
(Date:7/22/2014)... CA (PRWEB) July 22, 2014 ... provider of enterprise Time and Attendance / Workforce ... Iowa, a NOVAtime 3000 customer since 2007, has ... licensed version of NOVAtime’s state-of-the-art, web-based time and ... Services in Iowa (LSI) is a human services ...
(Date:7/22/2014)... Most people encounter the same two problems when trying to ... is a fast metabolism. These are hard problems to counteract on ... help fight these problems and to finally gain weight. , The ... who just can’t seem to eat more than a couple bites ... cause of this problem can vary. For some it can be ...
(Date:7/21/2014)... and kill cancer cells could boost the effectiveness of ... amputation, a new study reports. , Scientists at The ... a genetically engineered version of the virus used to ... virus alongside isolated limb perfusion chemotherapy given directly ... as an alternative to amputation was more effective ...
(Date:7/21/2014)... (PRWEB) July 22, 2014 iFitDress.com, a ... for women, has announced its exclusive collection of 2014 ... launched a promotion for its brand new gowns. , ... in the current market. Its sales boomed in the ... elegant products, but also because of the amicable services ...
Breaking Medicine News(10 mins):Health News:PhysicianOne Urgent Care Physicians Become Certified Medical Examiners for DOT Physicals 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CB-1 Weight Gainer Provides Two Tips to Help Customers Gain Weight 2Health News:Viral therapy could boost limb-saving cancer treatment 2Health News:Viral therapy could boost limb-saving cancer treatment 3Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2
... appropriate care and treatment for a disease “Haemophilia” that ... a defect in the genes the World Haemophilia Day ... incurable genetic disorder that is characterised by a deficiency ... usually affects ,males. ,India has some 1,00,000 patients ...
... Bengal, who gave birth to a baby in a public street ... a call for probes here Tuesday. // ,Bengali news ... village in Birbhum district, about 180 km from here, lying on ... leave a hospital in Siuri town. ,The district ...
... has revealed that at least a third of dentists are refusing ... opposite to what Prime Minister Tony Blair had said when he ... ,"The majority of the dentists are agreeing to the new contract, ... however, that I think around about 90 to 95 per cent ...
... results that 43 percent of older people with diabetes ... //This is when these two damages are most common ... been recommended by national diabetes-treatment guidelines for years hardly ... evidence that they can prevent heart attacks, strokes, kidney ...
... Well known food brands hold many families sway to their ... the garb of promoting healthy food culture. // This attitude ... that are unable able to digest the ingredients, labeling and ... ,Is that what brand building is all about? Adopting a ...
... 25,000 affected in a malaria epidemic in Assam, officials Tuesday said. ... preventive steps and cure those hit by the disease," Assam Health ... people had died of cerebral malaria since the beginning of April, ... hit. ,"We have been able to check the spread ...
Cached Medicine News:Health News:Beware Of A Silent Killer Called Haemophilia 2Health News:Older Diabetics not taking kidney and heart protective drugs 2
(Date:7/21/2014)... 2014 UBM Medica US announces that ... community for primary care clinicians offers a photo collection ... victims of a variety of summer scourges.  ... a host of medical menaces: poison ivy, tick-borne infections, ... the highlights covered on Consultantlive,s topic center that includes ...
(Date:7/21/2014)... 2014 By order of the U.S. Bankruptcy Court, ... of ophthalmic and optical equipment, designer eyeglass frames, and other ... American Optical Services LLC. Online bidding opens July ... succession, live auction style, on July 28 beginning at 10:30 ... be held July 25 th and 26 th ...
(Date:7/21/2014)... Israel , July 21, 2014 Galmed ... clinical-stage biopharmaceutical company focused on the development and commercialization ... liver diseases and cholesterol gallstones, announced today that it ... July 25, 2014 to discuss results for the period ... on current developments with respect to its clinical program ...
Breaking Medicine Technology:ConsultantLive Presents Special Coverage of Summer Scourges 2ConsultantLive Presents Special Coverage of Summer Scourges 3Auction Set For Assets Of National Optical Services Company 2Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2
... (NYSE Euronext Paris: COX) today announced that the ... with OA of the hip showed a highly,statistically ... of the trial. Naproxcinod 750 mg bid showed ... similar blood pressure profile,to placebo. Naproxcinod is the ...
... Nov. 21 Millions of Americans with moderate to severe ... new treatment option. Today, Johnson & Johnson Pharmaceutical Research ... Drug Administration (FDA) approved tapentadol immediate-release tablets for the relief ... of age or older. , , ...
Cached Medicine Technology:Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 2Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 3Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 4Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 3FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 4FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 6
... Helmer PC1200 Platelet Incubators ... your laboratory counter top. These ... institution to have the security ... environment without taking up a ...
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
... rotators and agitators for continual ... set at 22C (71F) or ... (59F to 104F). Uniformity is ... bottom. Recorder is standard on ...
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Medicine Products: